NASDAQ:BGLC BioNexus Gene Lab (BGLC) Stock Price, News & Analysis $5.15 -0.04 (-0.77%) Closing price 03:59 PM EasternExtended Trading$5.14 -0.01 (-0.19%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About BioNexus Gene Lab Stock (NASDAQ:BGLC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioNexus Gene Lab alerts:Sign Up Key Stats Today's Range$5.11▼$5.2650-Day Range$4.36▼$6.0052-Week Range$2.01▼$15.60Volume26,149 shsAverage Volume974,548 shsMarket Capitalization$9.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia. Read More BioNexus Gene Lab Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreBGLC MarketRank™: BioNexus Gene Lab scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for BioNexus Gene Lab.Read more about BioNexus Gene Lab's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioBioNexus Gene Lab has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.28% of the float of BioNexus Gene Lab has been sold short.Short Interest Ratio / Days to CoverBioNexus Gene Lab has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNexus Gene Lab has recently decreased by 73.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioNexus Gene Lab does not currently pay a dividend.Dividend GrowthBioNexus Gene Lab does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.28% of the float of BioNexus Gene Lab has been sold short.Short Interest Ratio / Days to CoverBioNexus Gene Lab has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNexus Gene Lab has recently decreased by 73.49%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.95 News SentimentBioNexus Gene Lab has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BioNexus Gene Lab this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added BioNexus Gene Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioNexus Gene Lab insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.70% of the stock of BioNexus Gene Lab is held by insiders.Percentage Held by InstitutionsOnly 18.85% of the stock of BioNexus Gene Lab is held by institutions.Read more about BioNexus Gene Lab's insider trading history. Receive BGLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNexus Gene Lab and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BGLC Stock News HeadlinesBioNexus Gene Lab Corp. (NASDAQ:BGLC) Short Interest Up 206.0% in SeptemberOctober 5, 2025 | americanbankingnews.comBioNexus Gene Lab Corp. BGLC (U.S.: Nasdaq) - The Wall Street JournalJuly 31, 2025 | wsj.comREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.October 16 at 2:00 AM | Paradigm Press (Ad)BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision OncologyJuly 30, 2025 | globenewswire.comBioNexus Gene Lab Corp. (BGLC) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comBioNexus Gene Lab Corp. (BGLC) Stock Price Today - WSJJuly 2, 2025 | wsj.comBioNexus Gene Lab Corp News (BGLC) - Investing.comJuly 2, 2025 | investing.comBioNexus Gene Lab Names Chong Set Fui as CFOJune 23, 2025 | marketwatch.comSee More Headlines BGLC Stock Analysis - Frequently Asked Questions How have BGLC shares performed this year? BioNexus Gene Lab's stock was trading at $2.7970 at the beginning of 2025. Since then, BGLC stock has increased by 83.9% and is now trading at $5.1450. How were BioNexus Gene Lab's earnings last quarter? BioNexus Gene Lab Corp. (NASDAQ:BGLC) released its quarterly earnings data on Monday, August, 18th. The company reported ($0.34) earnings per share for the quarter. The firm earned $2.26 million during the quarter. BioNexus Gene Lab had a negative trailing twelve-month return on equity of 35.54% and a negative net margin of 30.70%. When did BioNexus Gene Lab's stock split? BioNexus Gene Lab shares reverse split before market open on Monday, April 7th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did BioNexus Gene Lab IPO? BioNexus Gene Lab (BGLC) raised $5 million in an IPO on Thursday, July 20th 2023. The company issued 1,300,000 shares at a price of $4.00 per share. Network 1 Financial Securities acted as the underwriter for the IPO. How do I buy shares of BioNexus Gene Lab? Shares of BGLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioNexus Gene Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNexus Gene Lab investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/18/2025Today10/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:BGLC CIK1737523 Webwww.bionexusgenelab.com Phone60-1-2212-6512FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.60 million Net Margins-30.70% Pretax Margin-31.47% Return on Equity-35.54% Return on Assets-29.08% Debt Debt-to-Equity RatioN/A Current Ratio3.63 Quick Ratio2.94 Sales & Book Value Annual Sales$9.55 million Price / Sales0.98 Cash FlowN/A Price / Cash FlowN/A Book Value$4.63 per share Price / Book1.12Miscellaneous Outstanding Shares1,797,000Free Float1,784,000Market Cap$9.33 million OptionableNot Optionable Beta5.20 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:BGLC) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNexus Gene Lab Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNexus Gene Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.